ŠANGHAJ, 27. júna 2024 /PRNewswire/ — Spoločnosť Huawei sa zúčastňuje na veľtrhu MWC v Šanghaji 2024 pod heslom „Pokrok v inteligentnom svete” a ponúka „Komerčné zážitkové prehliadky 5G”. Spoločnosť Huawei vo svojom stánku v hale N1 na veľtrhu SNIEC predstavuje svoje najnovšie produkty a…
Month: June 2024
MWCS 2024: Huawei sa púšťa do komerčného 5G-A pre éru mobilnej umelej inteligencie
ŠANGHAJ, 27. júna 2024 /PRNewswire/ — Spoločnosť Huawei sa zúčastňuje na veľtrhu MWC v Šanghaji 2024 pod heslom „Pokrok v inteligentnom svete” a ponúka „Komerčné zážitkové prehliadky 5G”. Spoločnosť Huawei vo svojom stánku v hale N1 na veľtrhu SNIEC predstavuje svoje najnovšie produkty a…
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 26, 2024 /PRNewswire/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and…
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, June 26, 2024 /PRNewswire/ — Harbour BioMed (the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and…
Grow Capital, Inc. (GRWC) Progress Update and Market Reclassification
HENDERSON, Nev., June 26, 2024 /PRNewswire/ — Grow Capital, Inc. (OTC: GRWC), a leading financial services and technology holding company, is excited to provide shareholders with a significant progress update. Since our last communication, Grow Capital, Inc. has made remarkable strides…
Grow Capital, Inc. (GRWC) Progress Update and Market Reclassification
HENDERSON, Nev., June 26, 2024 /PRNewswire/ — Grow Capital, Inc. (OTC: GRWC), a leading financial services and technology holding company, is excited to provide shareholders with a significant progress update. Since our last communication, Grow Capital, Inc. has made remarkable strides…
2bcloud Recognized as Winner of 2024 Microsoft Partner of the Year Award
NEW YORK, June 26, 2024 /PRNewswire/ — 2bcloud, a leading next-generation, multi-cloud managed service provider for tech companies on their cloud journey, today announced it has won the 2024 Microsoft Partner of the Year Award for Israel. The company was honored among a global field of…
2bcloud Recognized as Winner of 2024 Microsoft Partner of the Year Award
NEW YORK, June 26, 2024 /PRNewswire/ — 2bcloud, a leading next-generation, multi-cloud managed service provider for tech companies on their cloud journey, today announced it has won the 2024 Microsoft Partner of the Year Award for Israel. The company was honored among a global field of…
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
– EPKINLY is now the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL) – Bispecific antibodies are designed to induce targeted cell killing by engaging the immune system…
U.S. Food and Drug Administration Grants Second Approval for EPKINLY® (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma
– EPKINLY is now the first and only bispecific antibody approved in the U.S. to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL) – Bispecific antibodies are designed to induce targeted cell killing by engaging the immune system…
